In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|April 30, 2020
INTERPHEX Launches Online Resource for Pharma, Bio, and Device Content
Author(s)BioPharm International Editors
The platform provides access to case studies, new technologies, expert insight, published and peer-reviewed articles, webinars, news updates, videos, and interviews.
Advertisement
INTERPHEX announced on April 23, 2020 that it is launching RECONNEX 365, a year-round online resource for pharma, bio, and device development and manufacturing content and information.
The platform provides access to case studies, new technologies, expert insight, published and peer-reviewed articles, webinars, news updates, videos, and interviews, according to a company press release. Exhibitors at INTERPHEX on April 20–22, 2021 at the Javits Center in New York, NY will have the ability to digitally introduce new and existing technical content, technologies, and solutions, while attendees will be able to schedule onsite meetings to experience the products, technologies, and services.
"Our new online resource reimagines procurement strategies and enables one to stay connected to the industry and leading suppliers year-round, setting companies with procurement needs up for future success," said Kate Scott, event director, INTERPHEX, in the press release. "Leading suppliers continue to select INTERPHEX to feature their innovative technologies, products, and services designed to reduce cost, increase productivity, and maximize efficiency."
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5